Ye WZ, Peng SS, Hu YH, Fang MP, Xiao Y. Anti-melanoma differentiation-associated gene 5 and anti-Ro52 antibody-dual positive dermatomyositis accompanied by rapidly lung disease: Three case reports. World J Clin Cases 2023; 11(23): 5580-5588 [PMID: 37637698 DOI: 10.12998/wjcc.v11.i23.5580]
Corresponding Author of This Article
Yu Xiao, MD, Academic Research, Doctor, Department of Dermatology, The Central Hospital of Xiaogan, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, No. 6 People's Square, Xiaonan District, Xiaogan 432000, Hubei Province, China. yyyxy09@163.com
Research Domain of This Article
Dermatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 16, 2023; 11(23): 5580-5588 Published online Aug 16, 2023. doi: 10.12998/wjcc.v11.i23.5580
Anti-melanoma differentiation-associated gene 5 and anti-Ro52 antibody-dual positive dermatomyositis accompanied by rapidly lung disease: Three case reports
Wen-Zheng Ye, Shan-Shan Peng, You-Hong Hu, Mu-Ping Fang, Yu Xiao
Wen-Zheng Ye, You-Hong Hu, Mu-Ping Fang, Yu Xiao, Department of Dermatology, The Central Hospital of Xiaogan, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan 432000, Hubei Province, China
Shan-Shan Peng, Department of Respiratory and Critical Care Medicine, The Central Hospital of Xiaogan, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan 432000, Hubei Province, China
Author contributions: Xiao Y and Peng SS contributed to manuscript writing and editing, and data collection; Ye WZ, Xiao Y and Hu YH contributed to data analysis; Xiao Y and Fang MP contributed to conceptualization and supervision; All authors have read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient and her parents for the publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu Xiao, MD, Academic Research, Doctor, Department of Dermatology, The Central Hospital of Xiaogan, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, No. 6 People's Square, Xiaonan District, Xiaogan 432000, Hubei Province, China. yyyxy09@163.com
Received: May 9, 2023 Peer-review started: May 9, 2023 First decision: June 13, 2023 Revised: June 22, 2023 Accepted: July 18, 2023 Article in press: July 18, 2023 Published online: August 16, 2023 Processing time: 98 Days and 17.2 Hours
Abstract
BACKGROUND
Clinically amyopathic deramatomyositis was manifested as the various cutaneous dermatomyositis (DM) manifestations without muscle weakness. Anti-melanoma differentiation-associated gene 5 (anti-MDA5) and anti-Ro52 antibody-dual positive clinically amyopathic DM patients are at a high risk of developing rapidly progressive interstitial lung disease, and they exhibit an immensely high half-year mortality.
CASE SUMMARY
We presented three patients with anti-MDA5 and anti-Ro52 antibody-dual positive DM patients and we reviewed the previous studies on the link between anti-MDA5 and anti-Ro52 antibody-dual positive DM. Although we aggressively treated these patients similarly, but they all exhibited different prognoses. We reviewed the importance of clinical cutaneous rashes as well as the pathogenesis and treatment in the dual positive anti-MDA5 and anti-Ro52 associated DM.
CONCLUSION
Patients with anti-MDA5 anti-Ro52 antibody-dual positive DM should be accurately diagnosed at an early stage and should be treated aggressively, thus, the patient’s prognosis can be significantly modified.
Core Tip: In this study, we presented three rare cases of anti-melanoma differentiation-associated gene 5 (Anti-MDA5) and anti-Ro52 dual positive clinically amyopathic dermatomyositis (DM) accompanied by rapidly interstitial lung disease (ILD). Moreover, we reviewed the clinical manifesetations, pathogenesis and therapy about it. More imterestingly, there was a similarity between anti-MDA5 associated DM complicated rapidly progressive ILD and severe coronavirus disease 2019 pneumomia.
